| # | Country | Total Patents | |
|---|---|---|---|
| #1 | EPO (European Patent Office) | 5 | |
| #2 | Australia | 4 | |
| #3 | United States | 4 | |
| #4 | Canada | 3 | |
| #5 | China | 3 | |
| #6 | WIPO (World Intellectual Property Organization) | 2 | |
| #7 | Israel | 1 | |
| #8 | Mexico | 1 | |
| #9 | Norway | 1 | |
| #10 | New Zealand | 1 | |
| #11 | Poland | 1 | |
| #12 | South Africa | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Environmental technology |
| # | Name | Total Patents |
|---|---|---|
| #1 | Mcgrath Michael | 11 |
| #2 | Kuhne Frederich W | 9 |
| #3 | Kodelja Vitam | 7 |
| #4 | Engleman Edgar G | 5 |
| #5 | Meuer Stefan | 4 |
| #6 | Kuhne Frederich-Wilhelm | 3 |
| #7 | Kuhne F W | 3 |
| #8 | Engleman E G | 1 |
| #9 | Mcgraph M | 1 |
| #10 | Kuehne Friedrich W | 1 |
| Publication | Filing date | Title |
|---|---|---|
| EP1234060A2 | Evaluating and predicting clinical outcomes by gene expression analysis | |
| MXPA02001724A | Chemically-stabilized chlorite solutions for treating cancer and other diseases. | |
| EP1021196A2 | Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |